Recent Price Movement and Market Context
On 5 December 2025, Nath Bio-Genes (India) touched an intraday low of Rs.140.1, representing a 3.94% decline on the day and a 2.33% fall compared to the previous close. This marks the lowest price level for the stock in the past year, down from its 52-week high of Rs.238. The stock has recorded losses over the last four consecutive trading days, accumulating a negative return of 9.84% during this period.
In contrast, the broader market has shown resilience. The Sensex, after a negative start, rebounded sharply by 586.89 points to close at 85,712.37, just 0.52% shy of its 52-week high of 86,159.02. The index is trading above its 50-day moving average, supported by strong performances from mega-cap stocks. Nath Bio-Genes, however, is trading below all key moving averages including the 5-day, 20-day, 50-day, 100-day, and 200-day, indicating a weaker technical position relative to the market.
Financial Performance and Profitability Indicators
Over the past year, Nath Bio-Genes has generated a return of -28.49%, significantly underperforming the Sensex’s 4.83% gain. The company’s operating profits have shown a compound annual growth rate (CAGR) of -0.21% over the last five years, signalling stagnation in core earnings. Return on Equity (ROE) averaged 6.31%, reflecting modest profitability relative to shareholders’ funds.
Quarterly results for September 2025 reveal a decline in profit after tax (PAT) to Rs.0.93 crore, down by 16.1% compared to the previous quarter. Interest expenses over the latest six months stood at Rs.6.86 crore, rising by 30.17%, which may exert pressure on net margins. Additionally, cash and cash equivalents at half-year stood at a low Rs.0.74 crore, indicating limited liquidity buffers.
Under the radar no more! This Large Cap from Cement is emerging from turnaround with solid fundamentals intact. Discover it while it's still relatively hidden!
- - Hidden turnaround gem
- - Solid fundamentals confirmed
- - Large Cap opportunity
Investor Participation and Market Sentiment
Institutional investors have reduced their holdings in Nath Bio-Genes by 1.58% over the previous quarter, now collectively holding just 1.08% of the company’s shares. This decline in institutional participation may reflect a cautious stance given the company’s recent financial trends and relative underperformance.
Over the last three years, the stock has consistently underperformed the BSE500 index, reinforcing a pattern of subdued market confidence. Despite this, the company’s return on capital employed (ROCE) stands at 5.8%, and the enterprise value to capital employed ratio is 0.5, suggesting an attractive valuation relative to capital utilisation.
Valuation and Peer Comparison
Nath Bio-Genes is trading at a discount compared to the average historical valuations of its peers within the Other Agricultural Products sector. While the stock’s profits have shown a modest rise of 3.5% over the past year, the price-to-earnings-to-growth (PEG) ratio is 1.9, indicating a valuation that factors in growth expectations.
Why settle for Nath Bio-Genes (India) ? SwitchER evaluates this Other Agricultural Products micro-cap against peers, other sectors, and market caps to find you superior investment opportunities!
- - Comprehensive evaluation done
- - Superior opportunities identified
- - Smart switching enabled
Sector and Industry Context
Nath Bio-Genes operates within the Other Agricultural Products sector, a segment that has experienced varied performance across companies. The stock’s recent price action and financial metrics place it at a distinct disadvantage compared to broader market indices and some sector peers. The company’s market capitalisation grade is rated 4, reflecting its size and market presence within the industry.
Despite the broader market’s positive momentum, led by mega-cap stocks and a Sensex trading near its 52-week high, Nath Bio-Genes remains under pressure. The stock’s technical indicators, including its position below all major moving averages, underscore the challenges it faces in regaining upward momentum.
Summary of Key Metrics
To summarise, Nath Bio-Genes’ stock price has declined to Rs.140.1, its lowest level in the past year, following a series of negative returns over recent sessions. The company’s financial indicators reveal subdued profitability, rising interest costs, and limited cash reserves. Institutional investor participation has diminished, and the stock continues to trail benchmark indices and sector averages.
While valuation metrics suggest the stock is trading at a discount relative to capital employed and peer valuations, the overall market assessment remains cautious given the company’s recent performance trends.
Limited Time Only! Upgrade now and get 1 Year of Stock of the week worth Rs. 14,999 for FREE. Don't miss out on this exclusive offer. Claim Your Free Year →
